Abstract
BackgroundProprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an important but underutilised option to help optimise lipid management. We developed a new service to improve patient access to these medicines...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have